PRNewsWire
22 Oct 2026, 18:40 UTC · 1h ago
Impact · against what's priced in
The news is already reflected in the stock price, as the 39.1% drop occurred immediately following the FDA's second Complete Response Letter in June. The ongoing securities class action is a trailing consequence of that event and does not introduce a new material catalyst.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
The FDA issued a second Complete Response Letter on June 30, 2026, for oxylanthanum carbonate due to repeating third-party manufacturing deficiencies.
Priced indisclosed on June 30, 2026
So whatThe stock's 39.1% drop to $4.69 suggests a significant write-down of the asset's NPV due to repeated regulatory failure.
More negative than 99% of claims this week
Continue reading
5 related stories
The FDA's second Complete Response Letter regarding oxylanthanum carbonate manufacturing deficiencies already triggered a 39.1% price collapse to $4.69. The subsequent class action lawsuit regarding these disclosures represents a secondary legal risk.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
A securities class action lawsuit (Patel v. Unicycive Therapeutics, Inc.) was filed on September 3, 2026, alleging failure to disclose manufacturing risks.
Priced infiled on September 3, 2026
So whatLegal reserves or settlement costs could impact the balance sheet in late 2026 or 2027.
More negative than 76% of claims this week
The FDA raised no concerns regarding the clinical safety or efficacy of the drug in its latest review.
Priced indisclosed on June 30, 2026
More positive than 55% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a securities fraud class action lawsuit following a 39.1% stock drop caused by FDA manufacturing deficiencies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
11h ago
+2.2%
Price is moving against the score
$3.96 vs $3.87 close before publication (Oct 21) · not market-adjusted
UNCY chart →
